系统文献综述比较肝素结合膨体聚四氟乙烯移植物与自体大隐静脉移植物治疗膝下外周动脉疾病的临床效用
本系统文献综述比较肝素结合膨体聚四氟乙烯与自体大隐静脉在膝下旁路术中的临床结局。检索MEDLINE和Embase后纳入8项回顾性队列研究,Meta分析显示两者在1至4年的一期通畅率、二期通畅率、保肢率和死亡率均无显著差异,所有分析因人群异质性和随访脱落被评为高偏倚风险。
要点
- 8项回顾性队列研究的Meta分析显示,肝素结合膨体聚四氟乙烯与自体大隐静脉在膝下旁路术中1至4年的一期通畅率无显著差异。
- 二期通畅率、保肢率和死亡率在所有时间点均无显著差异,仅胫动脉旁路的敏感性分析亦未发现差异。
- 所有分析因研究人群异质性和随访脱落被评为高偏倚风险。
核心结论
- Meta分析表明,自体大隐静脉与肝素结合膨体聚四氟乙烯在4年内的通畅率、保肢率和死亡率方面结局相似。
- 使用肝素结合膨体聚四氟乙烯人工血管是预防截肢的满意选择,尤其当自体大隐静脉移植物不可用时。
- 需要对照临床研究以进一步指导膝下移植物构建中移植物选择相关的未来决策和经济建模。
研究设计与样本
- 系统文献综述,在MEDLINE和Embase进行电子文献检索,以识别膝下外科旁路术患者的比较性研究。
- 由两名独立评价者按预定义纳入标准进行摘要和全文筛选,并评估偏倚风险。
- 使用Review Manager 5软件(Nordic Cochrane Centre)进行Meta分析。
- 共纳入8项回顾性队列研究。
主要发现
- 一期通畅率Meta分析显示肝素结合膨体聚四氟乙烯与自体大隐静脉在1年(比值比0.91,95%置信区间[0.52-1.59];P=0.74)、2年(1.12[0.60-2.10];P=0.77)、3年(0.62[0.26-1.48];P=0.28)和4年(0.70[0.36-1.39];P=0.31)无显著差异。
- 二期通畅率在1年(0.62[0.33-1.15];P=0.13)、2年(0.83[0.32-2.13];P=0.69)、3年(0.60[0.27-1.32];P=0.20)和4年(0.66[0.32-1.36];P=0.26)无显著差异。
- 自体静脉与肝素结合膨体聚四氟乙烯在保肢率和死亡率方面所有时间点均无显著差异。
- 仅纳入胫动脉旁路的流出道血管敏感性分析未发现差异。
- 所有分析因研究人群异质性和随访脱落被评为高偏倚风险。
临床怎么用
- 作者认为,使用肝素结合膨体聚四氟乙烯人工血管是预防截肢的满意选择,尤其当自体大隐静脉移植物不可用时。
- 作者指出,需要对照临床研究以进一步指导膝下移植物构建中移植物选择相关的未来决策和经济建模。
局限性
- 所有分析因研究人群异质性和随访脱落被评为高偏倚风险。
- 需要对照临床研究以进一步指导膝下移植物构建中移植物选择相关的未来决策和经济建模。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This systematic literature review compares the clinical outcomes of heparin-bonded expanded polytetrafluoroethylene with autologous saphenous vein in the management of patients undergoing below-the-knee bypass to treat peripheral arterial disease. METHODS: An electronic literature search was conducted in MEDLINE and Embase to identify comparative studies in patients who underwent below-the-knee surgical bypass. Studies were screened at abstract and full text review using predefined inclusion criteria by two independent reviewers and critically appraised for risk of bias. Meta-analyses were conducted using Review Manager 5 software (Nordic Cochrane Centre). RESULTS: Eight retrospective cohort studies were identified. Meta-analysis of primary patency demonstrated no significant difference between heparin-bonded expanded polytetrafluoroethylene and autologous saphenous vein grafts after 1 (odds ratio: 0.91, 95% confidence interval: [0.52-1.59]; P = .74), 2 (1.12 [0.60-2.10]; P = .77), 3 (0.62 [0.26-1.48]; P = .28), and 4 years (0.70 [0.36-1.39]; P = .31). Similarly, for secondary patency, no significant difference was detected at 1 (0.62 [0.33-1.15]; P = .13), 2 (0.83 [0.32-2.13]; P = .69), 3 (0.60 [0.27-1.32]; P = .20), and 4 years (0.66 [0.32-1.36]; P = .26). There was no significant difference between autologous veins and heparin-bonded expanded polytetrafluoroethylene for limb salvage and mortality at all time points. A sensitivity analysis to compare outflow vessels was conducted in only tibial bypass and identified no differences. All analyses were considered at high-risk bias because of heterogeneity in study populations and attrition in follow-up. CONCLUSIONS: This meta-analysis demonstrates similar outcomes between autologous saphenous vein and heparin-bonded expanded polytetrafluoroethylene for patency, limb salvage, and mortality through 4 years. The use of heparin-bonded expanded polytetrafluoroethylene synthetic grafts is a satisfactory option to prevent amputation, particularly when autologous saphenous vein grafts are not available. Controlled clinical studies are needed to further inform future decision-making and economic modeling related to the choice of conduit for below-the-knee graft construction.
引用
- Dexter DJ, O'Neill F, Neville RF, et al. Systematic literature review comparing clinical utility of heparin-bonded expanded polytetrafluoroethylene graft with autologous saphenous vein graft for the management of below-the-knee peripheral arterial disease. J Vasc Surg. 2024. PMID: 39025282. doi:10.1016/j.jvs.2024.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。